RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists. The course will be made available in both English and French. The anticipated start date of the course will be April 2018 and the course will be made available for one year after launch. 

Key Dates
Issue Date: January 15, 2018
Application Deadline Date: February 5, 2018 at 5:00 PM ET
Notification Date: February 20, 2018
Project End Date: March 2019

For more information, please see the full RFP here.
Questions asked in advance of the application deadline will be posted here. Updated January 25, 2018

Q: What is the minimum number of physicians required on the faculty?

A: For each accrediting body, there should be 2-3 physicians on the faculty.

Q: Who is the target audience?

A: Course is open to general physicians and health care professionals whose practice is relevant to prostate cancer, specifically targeting uro-oncologists and community urologists. As such, the course requires accreditation by the Royal College of Physicians and Surgeons of Canada and the College of Family Physicians of Canada.

Q: When will the course be made available?

A: The anticipated start date of the course will be April 2018. The timeline may be extended upon consultation, if required.
Q: Should the course content apply to all audiences?
A: Yes.
Q: What is the budget for this RFP?
A: We are open to reviewing different levels of solutions. Please present a quote that matches the objectives of the proposal.
​Q: How will faculty members be chosen for the accredited course?
A: Faculty members will be officially invited to participate in the program by the relevant accrediting organizations. PCC will discuss potential faculty members with the successful vendor who will make the recommendation to the accrediting organization.
Q: Does PCC already have a relationship with a not-for-profit group of HCPs with a formal governance structure, accountnable to and serving, among others, its physician members through: CPD, provision of healthcare and/or research?
A: PCC has a network of external stakeholders that includes physicians and healthcare providers in the prostate cancer field.
Q: The RFP indicates the services must be provided by one organization. Can the vendor work with partners that assist in promotion?
A: PCC will enter into a contract with one organization to provide the physician education course. Any external parties that the successful vendor choose to consult/work with for this project will be their sole discretion.
Q: Does PCC have a preferred translation provider with whom the successful vendor will partner?
A: No, however PCC does work with a company who has translated program content in the past and will disclose this information to the successful vendor upon request.
Q: Does PCC already have a bank of videos, images, etc. that the successful vendor may be able to tap into?
A: PCC will share any relevant assets that may be helpful for this course. New assets are also expected to enhance course delivery.
Q: Was the RFP formally circulated directly to a group of potential providers, or only posted on your website, or both?
A: Both.
Donate Now!

Subscribe to our free monthly e-newsletter!

* indicates required


PCC Spotlight
$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.

Researchers discover common markers of tumour hypoxia across 19 cancer types

Landmark pan-cancer study analyzes mutation signatures of low oxygen in more than 8,000 tumours

Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  

Click here for news archive